Proprietary Hot Melt Extrusion Services | AbbVie Contract Manufacturing

Proprietary Hot Melt Extrusion: Is Your Formulation Partner Truly Equipped to Solve Bioavailability?

Bioavailability failure is one of the most costly obstacles in oral drug development — and hot melt extrusion is one of the most powerful tools to overcome it. AbbVie Contract Manufacturing delivers proprietary hot melt extrusion services combining advanced HME technology, amorphous solid dispersion expertise, polymer science, and cGMP-compliant formulation development for pharmaceutical executives seeking a decisive development advantage. From early feasibility through commercial HME manufacturing, our integrated CDMO platform addresses solubility enhancement, bioavailability optimization, controlled release formulation, and regulatory CMC strategy under one trusted, client-focused pharmaceutical partnership built for complex molecules and demanding timelines.

The Bioavailability Problem That Is Costing Your Drug Program

Nearly forty percent of new molecular entities entering development today suffer from poor aqueous solubility — and poor solubility means poor bioavailability, unpredictable clinical performance, and compromised commercial potential. For pharmaceutical executives managing pipeline investments, this is not a chemistry problem. It is a business problem. It erodes development ROI, extends timelines, and in the worst cases, terminates programs that carry significant therapeutic and commercial promise.

Proprietary hot melt extrusion is one of the most clinically validated and commercially proven technologies available to solve this challenge. At AbbVie Contract Manufacturing, our HME services are built on decades of formulation science leadership — combining proprietary extrusion technology, deep polymer expertise, and an integrated pharmaceutical CDMO infrastructure that transforms solubility-limited molecules into high-performing oral drug products.

"Bioavailability is not a formulation footnote — it is a commercial imperative. AbbVie Contract Manufacturing's hot melt extrusion platform was built to make that imperative achievable for even the most challenging molecules."

Consider the position of a pharmaceutical executive overseeing a promising oncology candidate with BCS Class II solubility characteristics and a Phase II timeline under pressure. Standard formulation approaches have failed to deliver the exposure levels required for clinical efficacy. The decision to partner with AbbVie Contract Manufacturing's HME services team changed the program trajectory entirely — delivering an amorphous solid dispersion formulation with significantly enhanced bioavailability within a development timeline that kept the clinical program on schedule.

What Makes AbbVie Contract Manufacturing's HME Platform Proprietary

Advanced Hot Melt Extrusion Technology Built for Complex Molecules

The word "proprietary" in pharmaceutical manufacturing carries significant weight. It signals not merely equipment ownership but accumulated scientific knowledge, process innovation, and formulation intelligence that cannot be replicated by simply purchasing an extruder. AbbVie Contract Manufacturing's proprietary hot melt extrusion platform represents precisely this depth — a uniquely integrated combination of advanced twin-screw extrusion technology, amorphous solid dispersion expertise, and formulation science that has been refined across hundreds of real-world drug development programs.

Our hot melt extrusion services are designed specifically for pharmaceutical executives who need more than contract manufacturing execution — they need a formulation partner capable of making intelligent, scientifically defensible decisions that protect both the molecule and the program investment. Key differentiators of our HME platform include:

• Proprietary twin-screw extruder configurations optimized for pharmaceutical processing
• Advanced polymer screening protocols for ASD formulation development
• Real-time process analytical technology integration for extrusion monitoring
• Thermal and rheological characterization capabilities for API-polymer compatibility
• Solubility enhancement track record across BCS Class II and IV molecules
• Scalable extrusion platform from milligram feasibility to commercial batch sizes
• Integrated downstream processing including milling, blending, and oral solid dosage manufacturing

Amorphous Solid Dispersion: The Science Behind the Advantage

At the heart of most successful HME formulation programs is amorphous solid dispersion — the conversion of a crystalline API into an amorphous form stabilized within a polymeric matrix. This transformation dramatically increases apparent solubility and dissolution rate, directly improving oral bioavailability for poorly soluble drug candidates. AbbVie Contract Manufacturing's scientists have deep, specialized expertise in amorphous solid dispersion design, polymer selection, and long-term physical stability management — expertise that directly determines whether an HME program delivers clinically meaningful results or falls short.

From Feasibility to Commercial HME Manufacturing: A Single Integrated Path

Protecting Program Investment Across Every Development Stage

For pharmaceutical executives, one of the greatest sources of development risk is the handoff between development and manufacturing — particularly when those functions reside with different organizations. Lost institutional knowledge, inconsistent process execution, and regulatory documentation gaps at transfer points are responsible for a disproportionate share of clinical and commercial setbacks. AbbVie Contract Manufacturing eliminates this risk entirely through an integrated HME development and manufacturing model that maintains scientific continuity from first feasibility experiment through commercial supply.

Our HME services span the complete development lifecycle. Early-phase programs benefit from rapid formulation feasibility assessments using our proprietary polymer screening methodology and high-throughput analytical characterization capabilities. As programs advance, our formulation scientists lead HME process development, design space establishment, and scale-up characterization — generating the process understanding required for robust CMC packages and regulatory submissions. At commercial scale, our pharmaceutical hot melt extrusion manufacturing operations deliver validated, cGMP-compliant production with the batch consistency and documentation rigor that commercial drug launches demand.

Development stage capabilities include:

• Rapid HME feasibility screening with API-sparing protocols
• Polymer and plasticizer selection for ASD stability optimization
• Solubility enhancement and dissolution profiling
• Thermal analysis, modulated DSC, and XRPD for solid-state characterization
• HME process development and design space mapping
• Scale-up from lab extruder through pilot and commercial HME equipment
• Downstream processing: hot-face pelletizing, strand milling, and tablet compression
• Full cGMP commercial HME manufacturing with validated processes

"Our integrated model means the scientist who designed the formulation is the same expert advising on commercial manufacturing. That continuity is irreplaceable when regulatory reviewers ask questions your CMC package must answer." — AbbVie Contract Manufacturing Formulation Science Leadership

Regulatory Strategy and CMC Excellence in HME Programs

Building Regulatory Confidence Into Every HME Decision

Pharmaceutical executives know that a technically superior formulation means little if the regulatory strategy behind it is weak. Hot melt extrusion programs introduce specific CMC complexity — amorphous form characterization and stability justification, polymer supplier qualification, process parameter controls, and dissolution method development all require careful regulatory design from the outset. AbbVie Contract Manufacturing embeds regulatory intelligence into HME programs at the earliest feasibility stage, ensuring that scientific decisions and regulatory requirements are aligned throughout development.

Our regulatory affairs and HME formulation teams collaborate to deliver CMC documentation packages that reflect the full scientific rigor of our development work. This includes amorphous solid dispersion characterization reports, polymorphic stability data, dissolution method validation, process validation protocols, and complete drug product manufacturing records — all structured to meet FDA, EMA, and ICH Q8–Q11 expectations. For pharmaceutical executives targeting fast-track designations, our regulatory team provides the CMC strategy expertise to support Breakthrough Therapy, Accelerated Approval, and Priority Review submissions.

Regulatory deliverables for HME programs include:

• ICH Q8-aligned pharmaceutical development reports for HME drug products
• Amorphous solid dispersion stability justification and ICH Q1 stability programs
• Process analytical technology implementation reports
• Dissolution method development and validation per USP and FDA guidance
• FDA Type B meeting preparation and CMC briefing document support
• CTD Module 3 drug substance and drug product documentation
• Scale-up and post-approval change management strategies

The Executive Case for Choosing AbbVie Contract Manufacturing's HME Platform

Why Pipeline Investment Decisions Point to AbbVie Contract Manufacturing

For pharmaceutical and biotech executives evaluating HME services partners, the decision framework extends well beyond technical capability lists. The questions that matter at the executive level are fundamentally about risk, speed, and return on development investment. Will this partner protect our timeline? Will their regulatory strategy hold up under FDA scrutiny? Can they scale reliably without process drift? Will our IP be protected throughout the engagement?

AbbVie Contract Manufacturing answers each of these questions with demonstrated performance rather than promises. Our proprietary hot melt extrusion platform has supported drug programs across oncology, CNS, cardiovascular, immunology, and rare disease — delivering formulation solutions for molecules that other CDMOs have declined as too complex. Our integrated development-to-manufacturing model compresses timelines by eliminating inter-vendor technology transfers. Our quality systems have withstood multiple FDA and EMA inspections without critical observations. And our IP protection frameworks — built on compartmentalized project structures, confidentiality-first contracting, and secure data governance — give executive sponsors the assurance they need to share proprietary molecular information with confidence.

Our HME CDMO services deliver measurable executive-level value through:

• Reduced development risk through integrated formulation-to-manufacturing continuity
• Compressed timelines via parallel workstreams and rapid feasibility protocols
• Stronger regulatory packages built on ICH Q8–Q11 quality by design principles
• Protected IP through contractual and operational security frameworks
• Commercial supply reliability through validated, scalable HME manufacturing
• Single-partner accountability across the full HME program lifecycle

Frequently Asked Questions About Hot Melt Extrusion Services

Questions sourced from Google People Also Ask and active pharmaceutical executive and formulation science search behavior.

Q1: What is hot melt extrusion in pharmaceutical manufacturing?

Hot melt extrusion is a continuous pharmaceutical processing technology in which an active pharmaceutical ingredient is mixed with thermoplastic polymers and excipients, then processed through a heated extruder barrel using rotating screws to produce a homogeneous solid dispersion. The resulting extrudate — typically in strand, pellet, or sheet form — is then milled or shaped into oral solid dosage forms such as tablets or capsules. HME is particularly valued for its ability to convert poorly soluble crystalline APIs into amorphous solid dispersions, dramatically improving aqueous solubility and oral bioavailability. AbbVie Contract Manufacturing's proprietary HME platform delivers this capability at every scale from feasibility through commercial manufacturing.

Q2: What types of drugs benefit most from hot melt extrusion?

Hot melt extrusion delivers the greatest benefit for BCS Class II and Class IV drug compounds — molecules with low aqueous solubility that consequently show poor or variable oral bioavailability. These include many oncology, CNS, antiviral, and immunology candidates where solubility limitations would otherwise prevent adequate drug exposure at clinically relevant doses. HME is also highly effective for controlled release formulation development, taste masking of bitter APIs, and fixed-dose combination products. AbbVie Contract Manufacturing's HME services team evaluates each molecule's physicochemical profile, thermal stability, and polymer compatibility to determine whether hot melt extrusion is the optimal bioavailability enhancement strategy for the specific program.

Q3: What is an amorphous solid dispersion and why is it important?

An amorphous solid dispersion is a molecular-level mixture of an API in its amorphous — non-crystalline — form within a stabilizing polymer matrix. Because amorphous drug substance has significantly higher apparent solubility and faster dissolution than its crystalline counterpart, amorphous solid dispersions can dramatically increase the oral bioavailability of poorly soluble drugs. The polymer matrix prevents the amorphous API from recrystallizing during storage, maintaining the solubility advantage over the product shelf life. Hot melt extrusion is one of the two primary manufacturing technologies — alongside spray drying — used to produce amorphous solid dispersions at pharmaceutical scale. AbbVie Contract Manufacturing has deep specialized expertise in ASD design, polymer selection, and long-term physical stability optimization.

Q4: How does hot melt extrusion compare to spray drying for solubility enhancement?

Both hot melt extrusion and spray drying are established technologies for producing amorphous solid dispersions, and both are used extensively in pharmaceutical development. HME is a solvent-free, continuous process well suited for thermally stable APIs — offering advantages in scalability, process simplicity, and elimination of solvent handling requirements. Spray drying uses solvent-based processing and is preferred for thermally labile molecules or APIs with limited polymer compatibility in the melt phase. The optimal technology choice depends on the API's thermal stability, solubility in organic solvents, required particle morphology, and downstream processing requirements. AbbVie Contract Manufacturing's formulation scientists conduct head-to-head feasibility assessments to identify the most scientifically and commercially appropriate technology for each program.

Q5: What regulatory considerations apply to HME drug products?

HME drug products face specific CMC regulatory considerations including justification of the amorphous solid dispersion state and its long-term physical stability, dissolution method development and discriminating method qualification, polymer and plasticizer supplier qualification under ICH Q7, process parameter control strategy documentation under ICH Q8, and stability program design per ICH Q1A and Q1B. For FDA submissions, the pharmaceutical development section of the CTD Module 3 must clearly document the scientific rationale for HME technology selection, the design space for critical process parameters, and the link between process controls and product quality attributes. AbbVie Contract Manufacturing's regulatory and formulation teams build this documentation rigor into every HME program from the outset.

Q6: What is the typical timeline for an HME formulation development program?

HME formulation development timelines depend heavily on molecular complexity, the number of polymer candidates requiring screening, downstream processing requirements, and the target development stage. A focused feasibility and prototype development program — generating an initial HME formulation with promising dissolution and stability characteristics — typically requires eight to sixteen weeks. Full formulation development through clinical batch manufacture, including process development, analytical method development, and cGMP batch production, generally spans six to eighteen months. AbbVie Contract Manufacturing compresses these timelines through parallel workstreams, high-throughput polymer screening capabilities, and an integrated development-to-manufacturing model that eliminates vendor transition delays.

Q7: Can hot melt extrusion be used for controlled release drug products?

Yes. Hot melt extrusion is highly effective for developing controlled release oral drug products — including extended release, sustained release, and modified release formulations. By selecting appropriate polymer systems and optimizing extruder processing conditions, HME enables precise control over drug release kinetics through matrix diffusion, erosion, or osmotic mechanisms. This controlled release capability is particularly valuable for CNS, cardiovascular, and metabolic disease drugs where sustained plasma levels improve therapeutic efficacy and patient compliance. AbbVie Contract Manufacturing's HME services team has extensive experience designing controlled release HME formulations, supported by biorelevant dissolution modeling and in vitro-in vivo correlation development for regulatory submissions.

Q8: How scalable is hot melt extrusion from development to commercial manufacturing?

Hot melt extrusion is inherently well suited to scalability because the process is continuous and governed by defined screw geometry, temperature profiles, and throughput parameters that can be systematically characterized and transferred across extruder scales. Scale-up from lab to commercial HME manufacturing requires careful characterization of specific mechanical energy input, residence time distribution, and heat transfer coefficients — all of which AbbVie Contract Manufacturing addresses through formal process characterization studies and Design of Experiments methodology. Our HME platform spans lab-scale extruders through commercial-scale twin-screw systems, ensuring that the formulation and process developed at small scale delivers equivalent product quality and performance at full commercial production volumes.

Conclusion: Proprietary HME Services That Protect Your Pipeline Investment

Proprietary hot melt extrusion is not a commodity service. It is a scientifically advanced, strategically critical capability that requires deep polymer expertise, integrated development-to-manufacturing infrastructure, and regulatory intelligence embedded from day one. For pharmaceutical executives managing complex pipeline programs with bioavailability challenges, the choice of HME partner directly determines whether that program reaches patients — and reaches market.

AbbVie Contract Manufacturing delivers HME services built on proprietary technology, demonstrated formulation science leadership, and a client-focused CDMO model that protects both the science and the investment behind your drug program. From rapid feasibility through cGMP commercial manufacturing, our integrated platform gives your pipeline the bioavailability solution, regulatory confidence, and development efficiency it deserves.

What is the most significant bioavailability or formulation challenge your pipeline is currently facing — and how is your current development strategy addressing it? We welcome your perspective in the comments.